Editorial Board

Editors

  • A Cervantes, University of Valencia, Biomedical Research Institute, Inclivia, Department of Hematology and Medical Oncology, Valencia, Spain, Neurology
  • G. Curigliano, MD, PhD, European Institute of Oncology, Milan, Italy, breast cancer
  • G. Lenz, University Hospital Munster, Munster, Germany, molecular pathogenesis of aggressive lymphoma, NF-κB pathway, PI3K/AKT signalling, tumour microenvironment
  • R.A. Stahel, MD, University of Zurich, Zurich, Switzerland, lung and thoracic oncology

Editorial Board

  • S Aebi, Luzern, Switzerland, breast cancer and gynecological tumors
  • S. Banerjee, London, United Kingdom, Gynaecological cancers, ovarian, endometrial, cervical cancers, PARP inhibitors
  • D. Bedognetti, Doha, Qatar, Tumor Biology Immunology
  • J. Bellmunt, MD, Barcelona, Spain, Solid Tumor Oncology (GU & GI)
  • S Bielack, Stuttgart, Germany, pediatric oncology, adolescents and young adults with cancer, bone sarcoma 
  • J. Bruix, Barcelona, Spain, hepatocellular carcinoma, intrahepatic chilangiocarcinoma, diagnosis and treatment
  • R. Califano, MD, Manchester, United Kingdom, small cell lung cancer and non small cell lung cancer , egfr , alk and immunotherapy 
  • F. Cardoso, MD, Lisboa, Portugal, biology of breast cancer, prognostic and predictive markers of response to systemic therapy, and new anticancer agents
  • P. Casali, Milano, Italy, adult sarcomas, including gastrointestinal stromal tumours
  • A. Chan, Sydney, Australia, Head and neck cancers , Nasopharynx cancer, Epstein Barr Virus
  • R.C. Coleman, MBBS, MD, FRCP, Sheffield, United Kingdom, Cancer, Bone, Biomarkers, Bisphosphonates, Clinical trials
  • D. De Ruysscher, MD, PhD, Maastricht, Netherlands, radiation oncology
  • C. Dittrich, Wien, Austria, Methodology of clinical trials, Clinical trial regulation, Pancreatic cancer
  • R. Dziadziuszko, MD, PhD, Gdansk, Poland
  • T. Eisen, Cambridge, United Kingdom, Renal cell carcinoma, Drug development
  • M. Hutchings, Copenhagen, Denmark, lymphoma
  • K Jordan, Potsdam, Germany, Internal Medicine and Haematology and Oncology
  • M. Ladetto, Hemato-Oncology
  • F. Lordick, Leipzig, Germany, hematology and oncology
  • R.J. Mayer, Boston, Massachusetts, United States of America, hematology and oncology
  • O Michielin, Lausanne, Switzerland, translational oncology
  • C. Pezaro, Melbourne, Australia, Genitourinary cancer, Prostate cancer, Clinical research, Translational research.
  • M.R. Posner, New York, New York, United States of America, Hematology-Oncology, Cancer (Oncology)
  • A. Prat, Barcelona, Spain, breast cancer -omics, and clinical implementation of omic-based assays. Specialties: Breast Cancer Gene Expression Profiling
  • M. Preusser, Wein, Austria, characterization of inflammatory infiltrates and immune checkpoint molecules in cancer,  anti-cancer drugs including immunotherapies
  • S.A. Quezada, London, United Kingdom, Immune Regulation and Tumour Immunotherapy
  • C. Sessa, Bern, Switzerland, Obstetrics and Gynaecology, Pharmacology
  • J. Tabernero, MD, Barcelona, Spain, colorectal cancer
  • K. Tamura, Breast and Medical Oncology
  • P Tan, Singapore, Singapore, gastric cancer
  • M. Weller, Zurich, Switzerland, brain tumors and the diagnosis and therapy of glioblastoma and other primary brain tumors.
  • Y.L. Wu, MD, Guangzhou, China, Multidisciplinary therapy and translational medicine on lung cancer,  Evidence-based medicine in Oncology